Zensar Tech Q1: Healthy Earnings Update, Management Spoke About Profits Attain & Growth Plans Ahead?

Investec has maintained a hold rating for HUL and increased the target price to Rs 2,797 from Rs 2,439. The company’s Q1 performance slightly exceeded expectations across all metrics, with anticipated gradual improvement. Categories such as UVG were affected by Personal Care and Foods, while premium categories are expected to show stronger growth moving forward.

Hot stocks: Brokerage view on HUL, Zensar Tech, Kajaria Ceramics, Torrent Pharma, ICICI Pru and Bajaj Finance

Zensar Technologies reported 8.88% decreased in consolidated net profit to Rs 157.9 crore in Q1 FY25 as compared to Rs 173.3 crore in Q4 FY24.

Zensar Tech Q1 PAT slips 9% QoQ to Rs 158 cr

Upcoming results: Bajaj Finance, DCM Shriram, Heritage Foods, Hindustan Unilever, ICICI Prudential, ICRA, Indoco Remedies, ICICI Securities, Kajaria Ceramics, Mahindra and Mahindra Financial Services, Schaffler India, Sharda Cropchem, SRF, Steel Strips Wheels, Thyrocare Technologies, Torrent Pharmaceuticals, and United Spirits.

Stock Alert: Reliance Industries, Cyient DLM, Zensar Tech, Suzlon Energy, Federal Bank, Gensol Engineering

Zensar Technologies consolidated net profit rises 1.09% in the June 2024 quarter

Notable tech companies like Cigniti Technologies, Moschip Technologies, and Zensar Technologies will declare their first-quarter earnings on Monday.

Q1 Results Today: IDBI Bank, Suzlon Energy, Coforge, UCO Bank Among 40+ Firms To Declare Earnings

Zensar Technologies announced today the full acquisition of BridgeView Life Sciences LLC. The US]based leader in information technology and operations provides a comprehensive range of advisory, transformation, and managed services exclusively for life sciences customers endeavoring to launch products or new indications, assess and optimize their operations, or engage in merger or acquisition transactions. This strategic move strengthens Zensar’s Healthcare and Life Sciences (HLS) vertical and expands its pharma commercial and product launch expertise.

Corporate

Zensar acquires BridgeView Life Sciences to enhance its LHS offerings

The acquisition is expected to be completed tentatively within 2-3 weeks

Zensar acquires BridgeView to expand into biopharma, life sciences industry

Pune-based Zensar Technologies said in a statement, “This strategic move strengthens Zensar’s Healthcare and Life Sciences (HLS) vertical and expands its pharma commercial and product launch expertise.” The company is part of the $4.8 billion conglomerate RPG Group, has a total services revenue at $591.3 million as on FY24 with the US contributing to 67.2% of the revenue share.

Zensar Technologies to buy US firm BridgeView Life Sciences

The company witnessed sequential growth in all four verticals in Q4 FY24 after several quarters and expects this momentum to sustain in FY25.

Zensar Technologies - Margin Expansion In FY24; Revenue Growth Focus For FY25: Systematix

The management foresees stability in the company’s margins going forward and will expand with the growing volumes

Zensar Technologies - Strategic Focus Areas For Long-Term Growth: Axis Securities

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Zensar Technologies Limited is a software and infrastructure services company, which provides a range of information technology services and solutions.